Lotus Bio-Technology Development Corp.
LBTD · OTC
3/31/2017 | 3/31/2016 | 3/31/2015 | 3/31/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.06 | -0.00 | 19.36 | 0.04 |
| FCF Yield | -0.15% | -0.07% | 0.01% | -13.58% |
| EV / EBITDA | -593.09 | -26.60 | -968.06 | -5.16 |
| Quality | ||||
| ROIC | 1,132.84% | 7,928.93% | 41.42% | 227.99% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.01 | -0.08 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -18.46% | -1,099.20% | 106.09% | 65.90% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | -0.07 | 0.08 | -0.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |